CIRIUM
16.12.2021 09:02:12 CET | Business Wire | Press release
The new 2021 Cirium Fleet Forecast reveals that US$2.9 trillion is expected to be spent on approximately 45,000 new and more-fuel-efficient aircraft over the next 20 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005489/en/
Published by Ascend by Cirium, the consultancy arm of aviation analytics firm Cirium , the Cirium Fleet Forecast predicts that 20-year aircraft deliveries globally by 2040 will be 4% higher than previously predicted a year ago.
This outlines a positive outlook for the aviation industry and its recovery from the COVID-19 pandemic.
COVID-19 significantly affected air travel and so aircraft deliveries, with a 43% reduction during 2020 — 600 fewer aircraft — before the recovery in 2021, albeit still 25% below the 2019 level.
As vaccination programs have been increasing globally, air travel is reopening resulting in 300 more aircraft deliveries in 2021 — despite the issues surrounding Boeing’s 787.
Rob Morris, Global Head of Consultancy at Ascend by Cirium said: “The 2021 Cirium Fleet Forecast provides an optimistic long-term forecast for aviation which sees the industry return — although structurally differently to before — to more traditional growth paths beyond 2024. Passenger traffic is predicted to grow annually at 3.7% and so the global passenger fleet will be required to increase by almost 22,000 aircraft.”
“If this forecast is realised that would take the global passenger fleet to some 47,200 aircraft by the end of 2040. The aircraft deliveries that are predicted will not only meet the rising traffic demands but will also replace older less-fuel-efficient aircraft.”
China will receive the most deliveries
The number of aircraft deliveries will vary from airline region to region, with Asian markets expected to be the engine for growth.
China is forecast to have the highest passenger traffic growth rate at over 6% — making it the country with the largest amount of deliveries achieving a 20% share.
This is significantly ahead of all other Asia-Pacific countries, which have a combined 22% share in total.
North American airlines are forecast to have 20% share and European carriers to have 17%.
The Middle East is estimated to take a 7% share, but in value terms it will be 11% by virtue of the high number of twin-aisle aircraft deliveries.
Latin America mirrors that of the Middle East with a 7% share, followed by Russia and CIS on 4% and Africa at 3%.
Majority of deliveries will be single-aisle jets
The Fleet Forecast reveals that single-aisle jets will account for 70% of total aircraft deliveries and 55% of delivery value in the next 20 years.
The core of this US$1.6 trillion market continues to be the 150-seat size aircraft, typified by the Airbus A320neo and Boeing 737 Max 8, which will make up 50% of deliveries.
Popular 180+ seater aircraft, including the A321 neo and B737 Max 10, will take an increasing annual share, with 40% of deliveries over the two decades.
New single-aisle aircraft programs from both Airbus and Boeing are forecast to be developed in the early to mid-2030s.
The US$1.1 trillion twin-aisle aircraft market will focus on B787s and A350s, with ‘mid-sized’ 250-300 seaters taking some 65% of delivery value. The highest capacity markets will be fought over by the A350-1000 and B777-9.
Deliveries in the regional markets are forecast to be worth US$150 billion. Around a third of this figure is for turboprops, led by the 70-seat sector aircraft, with a larger 90-seat size from the 2030s. Future programs include China’s MA700 and an expected new series from Embraer.
Older fleets will be replaced with new generation aircraft
About 80% of the current passenger fleet is forecast to be retired from passenger service between 2021 and 2040.
The replacement of these older aircraft — which have higher fuel burn — with new models, is becoming more important as the industry looks to drive reductions in carbon emissions and focus on sustainability.
Overall, there will be some 19,000 retirements from the end-2020 passenger fleet, in addition to the early phasing out of several relatively young aircraft.
Ascend by Cirium’s analysis forecasts an average economic life of 22 years for single-aisle aircraft and 20 years for twin-aisle aircraft.
Freighters: New builds and conversions are rising
As cargo remains strong, freighter capacity (based on available tonne kilometers) is forecast to grow at 3.3% compared to 2019 and the supply of freighter aircraft is predicted to be around 3,500 aircraft over the next 20 years.
Of this total, 30% are expected to be newbuild freighters and 70% are conversions from passenger to freighter aircraft. Around 1,050 new aircraft are forecast worth US$121 billion.
Passenger-to-freighter conversions are being driven by the growth of e-commerce, which has been boosted by more online shopping during lockdowns.
These conversion programs are focused on newer-generation aircraft types, such as the A321, B737-800, A330 and B777-300ER.
The Cirium Fleet Forecast is an independent outlook of the global commercial passenger and freighter aircraft market, based on the largest data portfolio in aviation and years of expertise.
To download an Executive Summary of the 2021 Cirium Fleet Forecast, click here.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005489/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
